Compare TROX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROX | PRAX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.2M | 4.0B |
| IPO Year | 2005 | 2020 |
| Metric | TROX | PRAX |
|---|---|---|
| Price | $4.67 | $267.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $4.54 | ★ $304.43 |
| AVG Volume (30 Days) | ★ 4.9M | 1.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,844,000,000.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $2.86 | $26.70 |
| 52 Week High | $11.11 | $278.44 |
| Indicator | TROX | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 66.11 | 71.53 |
| Support Level | $4.27 | $251.00 |
| Resistance Level | $5.25 | $278.44 |
| Average True Range (ATR) | 0.33 | 17.08 |
| MACD | 0.12 | 6.49 |
| Stochastic Oscillator | 72.84 | 90.84 |
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.